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Background: We have reported promising outcomes using a staged approach, in which bortezomib/thalidomide/
dexamethasone was used only in 14 patients with suboptimal response to VAD (vincristine/adriamycin/
dexamethasone) before autologous stem cell transplantation (ASCT). Here we compared the outcomes of the
staged approach with frontline PAD (bortezomib/doxorubicin/dexamethasone) or VTD (bortezomib/thalidomide/
dexamethasone) induction, and analysed prognostic factors for outcome.
Patients and methods: Ninety-one transplant-eligible Chinese patients received three induction regimens prior to
ASCT [staged approach (N = 25), PAD (N= 31), VTD (N = 35)]. and received thalidomide maintenance for 2 years
post-ASCT.
Results: 43 (47.3%) patients had International Staging System (ISS) III disease. By an intention-to-treat analysis, the
overall CR/nCR rate were 37.4% post-induction, and 62.6% post-ASCT. Five-year overall (OS) and event-free (EFS)
survivals were 66% and 45.1%. There was no difference of the post-induction CR/nCR rate, EFS or OS between
patients induced by these three regimens. Moreover, ISS III disease did not affect CR/nCR rates. Multivariate analysis
showed that ISS and post-ASCT CR/nCR impacted OS while ISS and post-induction CR/nCR impacted EFS.
Conclusions: These three induction regimens produced comparable and favorable outcomes in myeloma. The
unfavorable outcome of ISS stage III persisted despite upfront/early use of bortezomib. CR/nCR predicted favorable
survivals.
Keywords: Myeloma, Staged approach, PAD, VTD, Prognostic factors, Deep vein thrombosisBackground
Bortezomib, a proteasome inhibitor, is an active agent
for the treatment of myeloma. Its efficacy was initially
demonstrated in the salvage treatment of refractory
myeloma patients, with a complete response (CR) rate of
9% [1,2]. Subsequently, a high CR rate has also been* Correspondence: jcschim@hku.hk
1Department of Medicine, Queen Mary Hospital, University of Hong Kong,
Hong Kong, Hong Kong
Full list of author information is available at the end of the article
© 2012 Chim et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orshown with the use of bortezomib-based regimens as in-
duction therapy for newly diagnosed myeloma patients
[3]. A post-induction CR rate of 43% and 30% was
observed when bortezomib-based induction regimens
were used in both transplant-eligible and transplant-
ineligible myeloma patients [4,5].
In Hong Kong, we have adopted a staged approach, in
which newly diagnosed, transplant-eligible myeloma
patients are risk-stratified according to their initial che-
mosensitivity. Patients who respond to vincristine,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Staged Approach.
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gous stem cell transplantation (ASCT). Patients who do
not respond optimally to VAD receive salvage therapy
with bortezomib/thalidomide/dexamethasone (VTD) be-
fore ASCT. This staged approach aims at employing
early bortezomib-based therapy in patients who do not
achieve a rapid cytoreduction after VAD, thereby restrict-
ing the use of the expensive bortezomib to patients with
suboptimal response to conventional treatment while en-
suring “early” bortezomib-based induction therapy. With
this strategy, a CR rate of 48% (by an intention-to-treat
analysis), and a 3-year overall survival of 75%, has been
achieved [6]. Based on this approach, we showed that
only 56% myeloma patients required salvage therapy with
VTD. During the same study period, two other
bortezomib-containing regimens VTD and PAD (borte-
zomib, doxorubicin, dexamethasone) were also used as
first-line treatment of myeloma patients.
In this report, we examined the hypothesis that mye-
loma patients treated by the staged approach, in which
early bortezomib-based induction is used in selected
patients, might achieve similar outcomes as compared
with patients receiving receiving frontline bortezomib-
based regimens.
Patients and methods
Patients
Ninety-one newly diagnosed, symptomatic, transplant-
eligible myeloma patients with measurable disease were
studied. Patients who were financially competent
received frontline therapy with bortezomib-containing
regimens. Other patients received a staged approach, and
were treated with bortezomib supported by philanthropy
only when the initial response was suboptimal.
Regimens
Staged approach
Twenty-five patients received initial cytoreduction with
three cycles of VAD (vincristine, adriamycin and dexa-
methasone). (Figure 1) Those achieving ≥ 75% reduction
in paraprotein proceeded to ASCT (N= 11; 44%).
Patients with< 75% reduction in paraprotein received
salvage therapy with four cycles of VTD (bortezomib:
1.3 mg/m2/day intravenously on days 1, 4, 8 and 11;
thalidomide: 200 mg/day; dexamethasone: 40 mg/d or-
ally from days 1–4 and days 8–11), and then ASCT
(N= 14; 56%). All patients received thalidomide (50-
100 mg/day) as maintenance therapy post-ASCT.
Bortezomib-containing regimens
During the same period, 66 patients received 4 cycles of
bortezomib-containing regimens (PAD, N= 31; and
VTD, N=35) followed by ASCT. Patients receiving
PAD had four 3-weekly cycles of chemotherapycomprising bortezomib 1.3 mg/m2/dose on days 1, 4, 8
and 11, adriamycin 9 mg/m2/d on days 1–4 and dexa-
methasone 20 mg/d days 1–4, and days 8–11. Patients
receiving VTD had four 3-weekly cycles of chemother-
apy comprising bortezomib 1.3 mg/m2/dose on days 1,
4, 8 and 11, thalidomide 200 mg/d, and dexamethasone
20 mg/d days 1–4, and days 8–11. All patients received
maintenance thalidomide (50-100 mg/day) for 2 years
post-ASCT.
Stem cell mobilization and conditioning
Stem cells were mobilized with cyclophosphamide
(3 g/m2 intravenously) and granulocyte-colony stimulat-
ing factor (300 microgram/day subcutaneously until
leucocyte recovery). At least 4 x 106 CD34+ cells/Kg re-
cipient body weight were collected. ASCT conditioning
regimen comprised intravenous melphalan 200 mg/m2.
Staging and laboratory investigations
Myeloma work-up included bone marrow examination,
skeletal survey, serum β2-microglobulin (β2M) level,
serum protein electrophoresis (SPE), urine protein elec-
trophoresis (UPE), serum or urine immunofixation,
paraprotein level assay and serum free light chain (FLC)
assay (Freelite, The Binding Site, Birmingham, UK) [7].
Fluorescence in-situ hybridization (FISH)
Detection of cytogenetic aberrations was performed on
myeloma cells in the bone marrow sample by FISH. En-
richment for myeloma cells was achieved by sorting with
CD138 immunomagnetic beads (MiniMACS, Miltenyi
Biotec, Auburn, CA) if the percentage of myeloma cells
were below 50% of all nucleated cells after haemato-
pathology review. The FISH probes (Abbott Molecular,
Abbott Park, IL) comprised the IGH/FGFR3 dual colour
dual fusion translocation probe for detection of t(4;14)
(p16;q32), the IGH/MAF dual colour dual fusion trans-
location probe for detection of t(14;16)(q32;q23) and
Table 1 Patient demographics and treatment outcomes
by regimen
Staged
Approach
N=25
PAD
N=31
VTD
N=35
p-value
(A) Demographics
Mean age 52.44 53.42 55.71 0.18
Male gender 17 (68 %) 15 (48.4 %) 18 (51.4 %) 0.296
Isotype 0.504
G 12 15 13
L 6 8 11
A 4 2 9
D 2 4 1
NS 1 2 1
ISS 0.83
I 7 (28 %) 11 (35.5 %) 11 (32.4 %)
II 7 (28 %) 5 (16.1 %) 6 (17.6 %)
III 11 (44 %) 14 (48.4 %) 17 (50 %)
High-risk Karyotype 3/5 (60 %) 2/6 (33.3 %) 4/12 (25 %) 0.35
(B) Outcomes
CR/nCR
post-induction
6 (24 %) 13 (41.9 %) 15 (42.9 %) 0.268
≥VGPR
post-induction
14 (56 %) 26 (83.9 %) 26 (74.3 %) 0.064
CR/nCR
post-ASCT
15 (62.5 %) 23 (74.2 %) 19 (63.3 %) 0.569
≥VGPR post-ASCT 19 (79.2 %) 29 (93.5 %) 27 (90 %) 0.242
5-year OS 59.80 % 78.70 % 73.80 % 0.661
5-year EFS 36.30 % 52.50 % 69.80 % 0.516
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deletion, in accordance with the International Myeloma
Workshop Consensus recommendation. At least 200 nu-
clei were analyzed and scored independently by two per-
sons. The cutoff for positivity was above 5% or at least
10 positive nuclei based on test validation data. High-
risk (HR) karyotypes include t(4;14), t(14;16) or del(17p).
Response criteria
All patients were analyzed on an intention-to-treat basis.
Bone marrow plasmacytosis and paraprotein levels were
assessed prior to treatment, after VAD, after VTD, and 3
and 6 months after ASCT. Responses were defined
according to standard criteria [8]. Complete remission
(CR) was defined as complete resolution of disease with
absent paraprotein, as evidenced by a negative SPE and
immunofixation, and <5% plasma cells in the bone mar-
row. Near-complete remission (nCR) was defined as a
negative SPE but positive immunofixation. Partial re-
sponse (PR) was subclassified into very good partial re-
mission (VGPR, paraprotein reduction >90%), and PR
(paraprotein >50% reduction). Minor response (MR)
was defined as paraprotein reduction of >25% but
<50%. No response (NR) was defined as paraprotein re-
duction of <25%. Progression was defined as >25%
paraprotein increase in two consecutive tests four weeks
apart. Relapse was defined as reappearance of the para-
protein on immunofixation in CR patients, positive SPE
in the nCR patients, and/or appearance of new bone
lesions. For patients with light chain myeloma, CR was
defined as normalization of the level and ratio of serum
FLC, and negative serum and urine immunofixation.
Statistical analysis
OS was defined as time from commencement of induc-
tion therapy to death or last follow-up. Event-free sur-
vival (EFS) was defined as time from commencement of
induction therapy to the date of progression, relapse or
death. Patients were clinically staged according to the
international staging system (ISS) [9]. Survival curves
were plotted by Kaplan-Meier method and compared by
the log-rank test. The association of diagnostic clinical
parameters (ISS) and treatment response (post-induction
CR/nCR or ≥VGPR, and post-ASCT CR/nCR and ≥
VGPR) with categorical variables including gender, ISS
stage, immunoglobulin isotype, post-induction CR/
VGPR or post-ASCT CR/VGPR was studied by Chi-
Square test, and age by Student’s t-test. Multivariate Cox
regression analysis was performed to analyze the impact
on OS and EFS of risk factors including pre-treatment
clinical characteristics including age, gender, ISS, isotype,
and post-treatment responses (post-induction CR/nCR
and ≥VGPR, or post-ASCT CR/nCR and≥VGPR) using
Statistical Package for the Social Sciences (SPSS) version16.0. Data on high-risk karyotype was only available in
27 patients, and hence not included in the multivariate
analysis. All p-values were two-sided.Results
Patients
There were 50 (54.9%) men and 41 (45.1%) women with
a median age of 55 years (range: 33–65 years). Apart
from one patient with insufficient data, there were 29
(32.3%) patients with International Staging System (ISS)
stage I, 18 (20%) stage II and 43 (47.7%) stage III disease.
There were 40 (44%) IgG, 25 (27.5%) light chain, 15
(16.5%) IgA, seven (7.7%) IgD and four (4.4%) non-
secretary myeloma cases. Of the 27 patients with karyo-
typic data, high-risk karyotype occurred in nine (33.3%)
[del(17p) in seven and t(4;14) in two]. The demographics
and clinical characteristics of patients receiving the
staged approach, PAD and VTD were outlined in Table 1.
There was no difference in the mean age, and the distri-
bution of gender, ISS, isotype or high-risk karyotypes be-
tween these three regimens, thereby permitting a valid
comparison of treatment outcomes.
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The post-induction CR/nCR rate were 24%, 41.9% and
42.9% in patients receiving the staged approach, PAD
and VTD respectively (p = 0.268). Post-induction ≥VGPR
rates were 56%, 74.2 % and 63.3% in patients receiving
the staged approach, PAD and VTD respectively
(p = 0.064). While there was a trend of lower ≥VGPR rate
in patients receiving the staged approach compared with
frontline PAD or VTD, the difference disappeared after
ASCT (post-ASCT ≥VGPR rate in staged approach, PAD
and VTD were 79.2%, 93.5% and 90%; p = 0.242). Of the
whole group of 91 patients, the overall CR/nCR rate
and ≥VGPR rates were 37.4% and 72.5% after induction
therapy, and 62.6% and 82.4% after ASCT.Prognostic indicators
To identify potential risk factors impacting the achieve-
ment of CR/nCR or ≥VGPR either post-induction or
post-ASCT, parameters including regimen, isotype, ISS
gender or presence of high-risk karyotype were corre-
lated with the achievement of CR/nCR and≥VGPR
post-induction and post-ASCT (Table 2). Of these fac-
tors, induction CR/nCR rate was not impacted byTable 2 Factors impacting post-induction CR/nCR, post-induc
Post-induction
CR/nCR (%)
Post-induction
Regimen
Staged approach 6 (24 %) 14 (56 %)
PAD 13 (41.9 %) 26 (83.9 %)
VTD 15 (42.9 %) 26 (74.3 %)
p-value 0.268 0.064
Age*
p-value 0.547 0.698
Gender
male 17 (34 %) 34 (68 %)
female 17 (41.45 %) 32 (78 %)
p-value 0.518 0.349
ISS
I 10 (34.48 %) 19 (65.5 %)
II 8 (44.44 %) 14 (77.8 %)
III 16 (37.21 %) 33 (73.3 %)
p-value 0.781 0.513
Isotype
G 8 (20.0 %) 23 (57.5 %)
L 14 (56.0 %) 20 (80 %)
A 7 (46.67 %) 13 (86.7 %)
D 2 (28.57 %) 6 (85.7 %)
NS 3 (75.0 %) 4 (100 %)
p-value 0.017 0.065
*: p-value refers to the comparison of the mean age of patients achieving or not acregimen (p= 0.268), ISS (p= 0.781) or gender (p= 0.518)
but impacted by isotype (p= 0.017) with lower post-
induction CR/nCR rate in those with IgG and IgD isotype.
Moreover, IgG isotype had a trend for lower≥VGPR rate
post-induction. In factors analysed for achievement
of post-ASCT responses, IgG isotype and male gen-
der were associated with lower CR/nCR rate but
none of these factors correlated with the achievement
of ≥VGPR post-ASCT. Interestingly, neither advanced
ISS (ISS III) nor high-risk karyotypes impacted on
CR/nCR rates or ≥VGPR rate after both induction
and ASCT.Survivals
In this combined cohort, the 5-year OS and event-free
(EFS) survivals were 66% and 45.1% (median EFS:
48 months) (Figure 2A & 2B). There was no difference
between the induction CR/nCR rate (p = 0.268), EFS
(0.516) or OS (p = 0.661) of patients induced by these
three regimens (Figure 3A & 3B). In univariate analysis,
ISS III (Figure 4A), male gender and failure of CR post-
ASCT (Figure 5A) predicted an inferior OS (Table 3). On
the other hand, ISS III (Figure 4B), failure of CR post-tion VGPR, post-ASCT CR/nCR and post-ASCT VGPR
≥VGPR (%) Post-ASCT
CR/nCR (%)
Post-ASCT≥VGPR (%)
15 (62.5 %) 19 (79.2 %)
23 (74.2 %) 29 (93.5 %)
19 (63.3 %) 27 (90 %)
0.569 0.242
0.416 0.730
27 (57.4 %) 40 (85.1 %)
30 (78.9 %) 35 (92.1 %)
0.04 0.501
20 (71.4 %) 26 (92.9 %)
13 (72.2 %) 16 (88.9 %)
24 (63.2 %) 32 (84.2 %)
0.431 0.559
18 (47.4 %) 33 (86.8 %)
18 (81.8 %) 19 (86.4 %)
11 (78.6 %) 13 (92.9 %)
6 (85.7 %) 6 (85.7 %)
4 (100 %) 4 (100 %)
0.013 0.908
hieving a response(CR/nCR or≥ VGPR).
Figure 2 (A) OS of combined cohort of 91 patients; (B) EFS of
combined cohort of 91 patients.
Figure 3 (A) OS by regimens(staged approach, PAD,VTD); (B)
EFS by regimens (staged approach , PAD, VTD).
Figure 4 (A) OS by ISS; (B)EFS by ISS.
Figure 5 (A) EFS by post induction CR/nCR; (B) OS of post-ASCT
/nCR.
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Table 3 Prognostic factors for overall survival (OS)
Univariate
analysis
Multivariate analysis
p-value p-value Hazard
Ratio
95% Confidence
Interval
regimen 0.661 0.320 0.622 0.245 - 1.584
gender 0.043 0.439 0.558 0.128 - 2.443
age 0.256 0.056 1.115 0.997 - 1.248
isotype 0.264 0.160 1.558 0.840 - 2.891
ISS 0.002 0.006 4.323 1.508 - 12.397
Post-induction CR/nCR 0.059 0.291 0.395 0.070 - 2.216
post-induction≥ VGPR 0.220 0.480 1.922 0.314 - 11.772
Post-ASCT CR/nCR 0.004 0.045 0.138 0.020 - 0.958
Post-ASCT VGPR 0.001 0.836 1.278 0.124 - 13.153
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dicted inferior EFS. In multivariate analysis, advanced
ISS and failure of post-ASCT CR/nCR predicted an infer-
ior OS, whereas advanced ISS and failure of CR/nCR
post-induction predicted a inferior EFS (Table 4).
Discussion
There are several observations from the study. Firstly,
despite this being a retrospective study, we showed that
there was no difference in EFS or OS in patients receiv-
ing the staged approach and those receiving frontline
PAD or VTD, suggesting that the staged approach
yielded comparable survivals as patients receiving front-
line bortezomib. This is encouraging because only half
[14 (56%)] of the patients receiving the staged approach
required salvage VTD, and hence the staged approach
could be used as a cost-effective but effective regimen in
less affluent countries, where frontline bortezomib might
not be affordable for the majority of the population.
However, while not reaching statistical significance due
to the small number of patients, it is notable that theTable 4 Prognostic factors for event-free survival (EFS)
Univariate
analysis
Multivariate analysis
p-value p-value Hazard
Ratio
95 % Confidence
Interval
regimen 0.516 0.751 0.907 0.495 - 1.661
gender 0.061 0.372 0.640 0.241 - 1.705
age 0.256 0.896 0.995 0.923 - 1.073
isotype 0.237 0.125 1.339 0.922 - 1.944
ISS 0.003 0.022 1.853 1.092 - 3.143
Post-induction CR/nCR 0.010 0.041 0.307 0.099 - 0.953
Post-induction VGPR 0.077 0.313 1.976 0.526 - 7.424
Post-ASCT CR/nCR 0.002 0.205 0.439 0.123 - 1.567
Post-ACST VGPR <0.001 0.116 0.275 0.055 - 1.374CR/nCR rate of patients receiving frontline bortezomib-
based induction was much higher than that of those
induced with the staged approach (42.9% versus 24%).
Moreover, the 5-year EFS of patients receiving frontline
bortezomib-based induction was almost double that of
those induced with the staged approach (69.8% versus
36.3%). Similarly, the 5-year OS of patients receiving
frontline bortezomib-based induction was much higher
than that of those induced with the staged approach
(73.8% versus 59.8%). Therefore, whether significant sur-
vival difference may emerge between the staged ap-
proach and PAD/VTD after prolonged follow-up
remains to be seen. Interestingly, while there was a trend
of lower ≥VGPR rate compared to patients receiving
PAD or VTD, the difference was abolished after ASCT.
Secondly, a high post-induction CR/nCR (PAD: 41.9%;
VTD: 42.9%) and ≥VGPR rates (PAD: 74.3%; VTD:
83.9%) were observed in patients receiving frontline
PAD or VTD induction. These post-induction CR/nCR
rates were comparable to other phase II studies, which
also reported a high post-induction CR/nCR rate after
PAD (29%) or CyBorD (46%) [4,10].
Thirdly, we attempted to analyse prognostic factors
impacting outcome in this combined cohort of myeloma
patients receiving either frontline (PAD/VTD induction)
or early bortezomib-based induction (in the staged ap-
proach). We showed that ISS III remained an important
adverse risk factor predicting both inferior OS and EFS,
despite patients receiving early or frontline bortezomib-
based induction regimens followed by ASCT. However,
there was no association between ISS III and presenta-
tion parameters including age, gender, isotype or even
high-risk karyotypes. Moreover, ISS III did not result in
an inferior CR/nCR or ≥VGPR rate either post-
induction or post-ASCT. Therefore, ISS III is a factor
that predicted residual chemo-refractory disease, thereby
leading to subsequent fatal relapse or disease progres-
sion. Indeed, the adverse prognostic impact of advanced
ISS stage for progression-free survival has also been
demonstrated in phase III studies [11,12]. Importantly,
ways to improve the survivals of ISS III myeloma
patients are urgently needed. In this connection, new
targeted agents or next generation immunomodulatory
agents are urgently required [13]. This is particularly im-
portant in this era of targeted therapy when the adverse
prognostic impact of high-risk karyotypes were shown to
be at least partially, if not totally, overcome by the use of
bortezomib-based induction regimens. [14] The persist-
ence of the unfavorable prognostic impact of advanced
ISS despite bortezomib-based induction poses an im-
portant therapeutic challenge.
In addition, we showed that post-induction CR/nCR
predicted a superior EFS, and CR/nCR post-ASCT a su-
perior OS. This is consistent with recent studies that
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predicting superior progression-free survival [11,12,15],
and CR/nCR post-ACST predicts superior OS [16].
In conclusion, a high CR/nCR and VGPR rates were
achieved in patients receiving frontline or early
bortezomib-based induction therapy, which was asso-
ciated with favorable OS and EFS. There was no differ-
ence between the outcomes of the staged approach and
frontline bortezomib-based induction regimens as PAD
or VTD. ISS stage III remains an adverse prognostic fac-
tor for both EFS and OS despite frontline or early
bortezomib-induction, and poses a therapeutic challenge
in this era of targeted therapy when the use of
bortezomib-based induction has at least partially abol-
ished the unfavorable impact of high-risk karyotypes.
CR/nCR post-induction and post-ASCT are favorable
factors predicting favorable OS and EFS, and hence are
important end-points of therapy.
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